Granules

Granules

Vertically integrated API and dosage manufacturer

Overview

Granules India makes APIs, PFIs, and finished dosages, using large-scale, vertically integrated plants that control production from base chemicals to final medicines. Its products include common off-patent APIs like Paracetamol, Ibuprofen, Metformin, and Guaifenesin, and it is expanding into more complex areas such as MUPS, oncology, and peptide therapies with US FDA approvals. The company differentiates itself through full vertical integration, large scale, and a global manufacturing footprint that supports both contract manufacturing and its own branded products, offering supply security and cost competitiveness. Its goal is to deliver reliable, affordable medicines to customers worldwide while growing capabilities in complex therapies and pursuing sustainable practices like green chemistry.

About Granules

Simplify's Rating
Why Granules is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

Industrial & Manufacturing

Biotechnology

Healthcare

Company Size

501-1,000

Company Stage

N/A

Total Funding

N/A

Headquarters

N/A

Founded

2014

Get referred to Granules

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q4FY26 revenue rose 23% year over year to ₹14,706 million on April 29, 2026.
  • Granules Life Sciences received NAI and VAI outcomes in 2026, validating expansion.
  • Net debt fell to ₹4,021 million in FY26, strengthening funding for launches.

What critics are saying

  • FDA's February 26, 2025 Gagillapur warning letter delays approvals for future U.S. launches.
  • March 30, 2026 Chantilly FDA observations prove compliance problems persist across sites.
  • If Gagillapur remediation fails, Granules loses its U.S. growth engine and valuation rerates lower.

What makes Granules unique

  • Granules controls APIs, PFIs, and finished dosages, driving low-cost, high-volume manufacturing.
  • The 2026 Senn Chemicals acquisition added peptides and Swiss CDMO capabilities.
  • Granules Pharmaceuticals launched CNS generics, including lisdexamfetamine, with 180-day exclusivity in 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Recently Posted Jobs

Sign up to get curated job recommendations

Granules is Hiring for 27 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →